BIO-TECHNE Corp (TECH) · Nov 3, 2026 · Other events
Dividend declared — $0.08 per share, unchanged from the prior quarter
Bio-Techne’s latest dividend keeps the quarterly payout at $0.08, with payment conditional on whether Merck’s acquisition closes before the record date.
Bio-Techne is a roughly $1.2 billion life-sciences tools company transitioning from standalone operations to an expected Merck KGaA acquisition; shareholders approved the deal in September, while closing remains targeted for late 2026 or early 2027, subject to remaining conditions.
The filing confirms a routine quarterly payout, not a new capital-allocation signal. Bio-Techne declared $0.08 per share for the quarter ended September 30, payable November 23 to holders of record November 13, provided the Merck transaction has not closed by then. The amount matches the prior quarterly dividend, so this is continuity rather than an increase or cut.
| Current | Prior quarter | |
|---|---|---|
| Quarterly dividend (Exhibit 99.1) | $0.08/share | $0.08/share |
The only incremental detail is the closing-date condition. The dividend will not be paid under this schedule if Merck completes the acquisition on or before November 13, making the transaction timeline the operative issue rather than the dividend itself. 〔0〕
Bottom line: This is housekeeping during the pending Merck sale: the dividend is unchanged and the business story is unaffected. The meaningful next event is deal completion, not the payout declaration.
Merck transaction closing, late 2026 or early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!